Exploring rapid learning in aging and memory disorders
Rapid Declarative Neocortical Declarative Learning in Aging and Memory
This study is testing how older adults and people with memory disorders can still learn and remember things despite having damage to a part of the brain called the hippocampus.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 94 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rennes University Hospital Academic / other |
| Locations | 1 site (Rennes) |
| Trial ID | NCT04846764 on ClinicalTrials.gov |
What this trial studies
The ANéRAVIMM project investigates how associative memory can persist despite hippocampal damage, particularly in aging and neurological diseases. It employs three experimental cognitive tasks to evaluate the effectiveness of different learning paradigms in patients with memory disorders. The first two tasks focus on the competition between learning systems affected by age, while the third task assesses the ability to create integrated memory representations of visual objects. This comprehensive approach aims to uncover the cognitive and cerebral bases of neocortical learning.
Who should consider this trial
Good fit: Ideal candidates include healthy volunteers aged 18-40 or 60-80, as well as patients with mild neurocognitive impairment or specific neurological conditions.
Not a fit: Patients with MRI contraindications or sensory deficits that interfere with the experiments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance memory rehabilitation strategies for patients with cognitive impairments.
How similar studies have performed: While the approach is innovative, previous studies have shown promise in understanding neocortical learning systems, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Healthy Volunteers * aged 18 to 40 years old and aged 60 to 80 years old * native French speaker * right-handed * with a level of education greater than or equal to the Certificate of Primary Education * free of any medical or psychiatric condition that may interfere with cognition Neurological patients * patients with mild neurocognitive impairment due to Alzheimer's disease * patients with semantic dementia syndrome * right-handed patients with a right or left unilateral surgical lesion of the anterior temporal lobe as a result of pharmaco resistant temporal epilepsy, with no seizures in the last 6 months, with a memory quotient greater than 75, and free of internal extra temporal lesions on MRI * patients with autoimmune limbic encephalitis who have been seizure-free for one month * 1 KA patient, suffering from the rare syndrome of developmental amnesia Exclusion Criteria: All participants * MRI contraindications * sensory deficit interfering with experimental tests * protected major (safeguard justice, trusteeship and guardianship) and persons deprived of liberty Healthy volunteers - deficit score on the MoCA scale according to current calibrations Neurologic patients * 7-items modified Hachinski ischemic score \>2 * dementia * epileptic seizure in the month prior to inclusion for epileptic patients undergoing surgery and limbic encephalitis patients
Where this trial is running
Rennes
- CHU Rennes — Rennes, France (Recruiting)
Study contacts
- Study coordinator: Pierre-Yves Jonin
- Email: Pierreyves.JONIN@chu-rennes.fr
- Phone: 02 99 28 25 76
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.